Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening

To determine the pancreatic phenotype of infants with cystic fibrosis (CF) diagnosed in the first week of life by a combined immunoreactive trypsin/mutation screening program. Design: A prospective evaluation of pancreatic function in infants with CF at the time of neonatal diagnosis and up to the age of 12. Setting: Two different centres (Verona, Italy and Westmead, Australia) to enable comparison of results between two regions where